title: Lack of correlation between fatty acid oxidation disorders and haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome?
abstract: OBJECTIVE
  Fatty acid beta-oxidation defects comprise a heterogeneous group of disorders that may precipitate acute life threatening metabolic crises particularly during catabolic episodes. Several studies have demonstrated a possible association between fatty acid beta-oxidation defects, including long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and severe pregnancy complications. However, the precise percentage of women with haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome associated with foetal fatty acid beta-oxidation defects is not known.
  
  
  METHODS
  We carried out a multicentre retrospective study on 88 infants, born to women with HELLP syndrome. Acylcarnitine profiles from blood dried on filter paper cards were analysed by tandem mass spectrometry for the diagnosis of fatty acid beta-oxidation defects. In addition, we screened for the common long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency mutation using a standard restriction fragment length polymorphism polymerase chain reaction method.
  
  
  RESULTS
  None of the infants studied carried the common long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency mutation. There was no evidence of fatty acid beta-oxidation defects, including long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, as expected by unremarkable acylcarnitine profiles, while three infants with fatty acid beta-oxidation defects were diagnosed in the control group.
  
  
  CONCLUSIONS
  Neither foetal long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency, including heterozygosity for the common long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency mutation, nor fatty acid beta-oxidation defects in general are a major risk factor for HELLP syndrome in Austria.
authors.affiliation: Department of Neonatology and Paediatric Intensive Care Medicine, University Hospital Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Holub
authors.forename: O A
authors.initials: OA
authors.lastname: Bodamer
authors.forename: C
authors.initials: C
authors.lastname: Item
authors.forename: A
authors.initials: A
authors.lastname: Mühl
authors.forename: A
authors.initials: A
authors.lastname: Pollak
authors.forename: S
authors.initials: S
authors.lastname: Stöckler-Ipsiroglu
mesh_terms: D015094:3-Hydroxyacyl CoA Dehydrogenases / Q000172:deficiency* / Q000235:genetics; D000328:Adult; D002331:Carnitine / Q000031:analogs & derivatives* / Q000097:blood*; D016022:Case-Control Studies; D004252:DNA Mutational Analysis; D005260:Female; D017359:HELLP Syndrome / Q000209:etiology*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008661:Metabolism, Inborn Errors / Q000150:complications* / Q000175:diagnosis*; D011247:Pregnancy; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: C116917:acylcarnitine; D015094:3-Hydroxyacyl CoA Dehydrogenases; D002331:Carnitine